4DMedical (ASX:4DX) has taken a significant step in the commercial rollout of its flagship CT:VQ technology. It announced that Stanford University has become the first US Academic Medical Centre to adopt the platform under a commercial agreement, less than two months after receiving clearance from the US Food and Drug Administration. …
4DMedical secures Stanford as first commercial site and expands AstraZeneca partnership in Brazil
October 23, 2025 Australian Biotech
Latest Video
New Stories
-
Arrotex launches new PBS-listed combination therapy as gap emerges in hypertension treatments
November 14, 2025 - - Latest News -
Sanofi building an AI-literate organisation through expectations, over experiments
November 14, 2025 - - Latest News -
Prospection says data access and leadership are critical to unlock AI’s potential in healthcare
November 14, 2025 - - Latest News -
The four 'H' words that can help drive the adoption of AI in health
November 14, 2025 - - Latest News -
Immutep posts encouraging Phase 2 results as 'Efti' spurs robust anti-tumour activity
November 13, 2025 - - Australian Biotech -
PYC Therapeutics appoints Peter Coleman as new Chair as part of board renewal
November 13, 2025 - - Australian Biotech -
New gene discoveries improve diagnosis of inherited heart disease
November 13, 2025 - - Australian Biotech